Table 1

Summary of the cohort studied

	JAK2^V617F and CALR mutation status				Total
Subtype	JAK2^V617F+	CALR^Mut	JAK2^V617F−/CALR^WT	Unknown	Total
Controls	–	–	15	–	15
PV	20	–	–	–	20
ET	26	9	6	31	72
MF*	18	14	5	16	53
Total	64	23	26	47	160

JAK2^V617F and CALR lesions did not coexist (ie, JAK2^V617F+ and CALR^Mut were mutually exclusive). All CALR mutations represent frameshift lesions in exon 9 of CALR.
*Includes both primary MF and ET/PV cases having undergone fibrotic transformation.
CALR, calreticulin; ET, essential thrombocythaemia; JAK2, Janus activated kinase 2; MF, myelofibrosis; Mut, mutated; PV, polycythaemia vera; WT, wild type.